Platt, LLC, et al. v. OptumRx, Inc.

District Court, N.D. California·Decided November 25, 2025·No. 3:25-cv-07018·Unknown

Opinion

PLATT, LLC, et al., Case No. 25-cv-07018-RS Plaintiffs, v. ORDER GRANTING REMAND OPTUMRX, INC., Defendant.

This action was filed in Alameda County Superior Court in September of 2020. Nearly five years later, defendants filed a notice of removal, asserting removal jurisdiction exists under the “federal officer removal statute,” 28 U.S.C. § 1442(a)(1), because plaintiffs seek to hold them liable for conduct they contend was “connected with” their “actions under a federal agency—the Veteran’s Health Administration (“VHA”).” Just under 30 days after that, defendants filed an “amended” notice of removal, still based on the theory that their challenged conduct was “connected with” their actions “under” the VHA, but adding the Centers for Medicare & Medicaid Services (“CMS”) as an additional agency “under” which they purportedly acted. Plaintiffs responded to the initial notice of removal with a motion to remand, contending the removal was untimely and that there was no substantive basis for removal. Plaintiffs responded to the amended notice of removal with a motion to strike it both on procedural grounds that it was grounds for removal was untimely. Plaintiffs also filed a separate motion to remand addressed to the amended notice of removal. The two motions to remand and the motion to strike were heard on November 21, 2025. For the reasons explained below, remand will be granted. Plaintiffs are 21 independent pharmacies. Defendant OptumRx, (“Optum”) is alleged to be a wholly owned subsidiary and/or affiliate of United Healthcare Group, Inc. Optum operates as a pharmacy benefits manager (“PBM”) for various health insurance plans. Under the terms of the parties’ contracts, plaintiffs fill prescriptions for Optum’s health plan clients and submit claims for reimbursement to Optum. Plaintiffs allege only a handful of PBMs dictate the reimbursement rates for dispensing brand and generic prescription drugs to patients. Optum purportedly controls approximately 25% of the national PBM market alone. Plaintiffs allege Optum has “systematically abused” its price-setting power in an attempt to drive independent pharmacies out of business, in breach of the contracts and its attendant duty of good faith and fair dealing. Plaintiffs contend Optum seeks to divert business that would otherwise go to local, independent pharmacies to its own affiliated “mail order” pharmacy. As noted, plaintiffs filed their original complaint in 2020. Optum contends the complaint did not disclose a basis for removal, and that therefore the 30-day period for removal following its receipt of the initial pleading was never triggered. See 28 U.S.C. § 1446(b)(1). Optum further argues the alternative 30-day period for removal specified in § 1446(b)(3) likewise never began to run. That section requires defendants to remove within 30 days once they receive “through service or otherwise, of a copy of an amended pleading, motion, order or other paper from which it may first be ascertained that the case is one which is or has become removable.” Optum contends it discovered the case was removable “based on its own investigation,” shortly after plaintiffs were granted leave to amend in state court this past summer. Optum does not argue the action only became removable upon the amendment; its position is no time limit for removal was ever triggered where the basis of removal was not apparent on the face of the complaint or from any subsequent pleading or other paper it received, and that it could properly remove whenever it happened to investigate and decide removal was available. Plaintiffs, in turn, argue Optum could not unilaterally extend its time to remove indefinitely. While plaintiffs do not press an argument that Optum’s time to remove was triggered by service of the original complaint (because it presumably implicated the “federal officer” issue from the outset), they contend the 30-day time to remove began to run no later than 2023, when Optum served discovery responses showing that it had processed 4,819 prescription drug claims identifying “VETERANS HEALTH ADMIN” as the insurance carrier. It is that very role of the VHA as an insurance carrier that Optum contends gives rise to “federal officer” removal. Optum, however, relies on case law suggesting that only a pleading or other paper served on the defendant, triggers the 30-day period of § 1446(b)(3), and therefore discovery responses that it served on plaintiffs are irrelevant. Technically, separate motions to remand addressed to the original and amended notices of removal likely are unnecessary. Either this matter should be remanded, or its should not, and a single motion could address the issues raised by both the original and the amended notices. Treating the two notices of removal separately, however, is useful for purposes of analysis. The flow chart is as follows: 1. Was the original notice of removal timely? If no, remand is required. 2. If the original notice was timely, is the invocation of “federal officer” jurisdiction viable? If yes, remand must be denied, and it will be unnecessary to consider the viability of the amended notice of removal. 3. If, and only if, the original notice was timely, but the invocation of “federal officer” jurisdiction is not viable with respect to the claim that defendants acted “under” the VHA, then the impact of the amended notice of removal must be evaluated. By defendants’ own arguments, the amended notice of removal is timely only if the initial notice of removal is timely. Accordingly, the issue will be whether that notice should be stricken based on failure to seek leave to file it. If so, then either the matter should be remanded, or defendants should be allowed the opportunity to seek leave to amend their notice. 4. If the amended notice is not stricken, the remaining question will be whether defendants can properly invoke “federal officer” jurisdiction with respect to the CMS, even though their arguments for jurisdiction arising from their interactions with the VHA have failed. A defendant has the right to remove to federal court “any civil action brought in a State court of which the district courts of the United States have original jurisdiction.” 28 U.S.C. § 1441(a). Most commonly, original jurisdiction exists when a state case presents a federal question, involves parties with complete diversity of citizenship plus at least $75,000 as the amount in controversy, or falls under maritime law. See 28 U.S.C. §§ 1331, 1332, 1333. Here, however, Optum invokes 28 U.S.C. § 1442(a)(1), which authorizes removal of actions against “any officer (or any person acting under that officer) of the United States or of any agency thereof . . . for or relating to any act under color of such office.”). To support removal on this basis, “Defendants must show: (1) they were “acting under” federal officers, (2) they can assert a colorable federal defense, and (3) Plaintiffs’ injuries were for or relating to Defendants’ actions.” City & Cnty. of Honolulu v. Sunoco LP, 39 F.4th 1101, 1106 (9th Cir. 2022) Ordinarily, “[i]t is to be presumed that a cause lies outside the limited jurisdiction of the federal courts.” Abrego v. Dow Chem. Co., 443 F.3d 676, 684 (9th Cir. 2006) (cleaned up). In the case of the federal

Free access — add to your briefcase to read the full text and ask questions with AI

Platt, LLC, et al. v. OptumRx, Inc., (N.D. Cal. 2025).

Platt, LLC, et al. v. OptumRx, Inc. (Platt, LLC, et al. v. OptumRx, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related